EirGenix Total Assets
EirGenix total assets. Based on the latest financial reports, EirGenix (6589) holds total assets worth NT$10.40 Billion TWD (≈ $327.71 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 6589 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of EirGenix (2017–2024)
Total assets of EirGenix from 2017 to 2024. This chart illustrates how EirGenix's total assets have evolved over time, based on quarterly financial data. See 6589 stock price for real-time trading data and today's change.
EirGenix - Asset Composition Analysis
EirGenix Total Assets Breakdown (December 2024)
EirGenix total assets breakdown as of December 2024. EirGenix's total assets of NT$10.40 Billion consist of 54.7% current assets and 45.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 37.7% |
| Accounts Receivable | NT$113.70 Million | 1.1% |
| Inventory | NT$552.09 Million | 5.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how EirGenix's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EirGenix (6589) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EirGenix's current assets represent 54.7% of total assets in 2024, an increase from 48.6% in 2017.
- Cash Position: Cash and equivalents constituted 37.7% of total assets in 2024, up from 24.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.1% of total assets.
EirGenix Competitors by Total Assets
Key competitors of EirGenix based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
EirGenix - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.86 | 13.25 | 2.60 |
| Quick Ratio | 6.02 | 12.10 | 2.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$3.85 Billion | NT$6.10 Billion | NT$1.11 Billion |
EirGenix - Advanced Valuation Insights
This section examines the relationship between EirGenix's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -2.6% |
| Total Assets | NT$10.88 Billion |
| Market Capitalization | $632.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values EirGenix's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: EirGenix's assets decreased by 2.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for EirGenix (2017–2024)
The table below shows the annual total assets of EirGenix from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$10.88 Billion ≈ $342.67 Million |
-2.56% |
| 2023-12-31 | NT$11.16 Billion ≈ $351.68 Million |
-5.78% |
| 2022-12-31 | NT$11.85 Billion ≈ $373.25 Million |
+3.55% |
| 2021-12-31 | NT$11.44 Billion ≈ $360.45 Million |
+198.31% |
| 2020-12-31 | NT$3.84 Billion ≈ $120.83 Million |
+12.21% |
| 2019-12-31 | NT$3.42 Billion ≈ $107.68 Million |
+14.87% |
| 2018-12-31 | NT$2.98 Billion ≈ $93.74 Million |
+75.49% |
| 2017-12-31 | NT$1.70 Billion ≈ $53.41 Million |
-- |
About EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more